人類胰島素製劑市場：按產品類型、按應用、按地區

預計2024年全球人類胰島素製劑市場規模為524.7億美元，預計2031年將達926.3億美元，2024年至2031年複合年成長率為8.5%。

圖 1. 2024 年人類胰島素製劑市場佔有率（%），依地區分類

由於世界各地糖尿病盛行率不斷上升，過去幾年全球人類胰島素製劑市場穩定成長。人類胰島素製劑是正常人類胰島素的生物合成版本，用於治療和管理糖尿病。根據國際糖尿病聯盟發布的資料，2019年約有4.63億成年人患有糖尿病，預計2045年將增加至7億人。糖尿病人口的不斷成長、胰島素治療意識的提高以及胰島素筆和胰島素幫浦等創新胰島素輸送系統的推出預計將推動全球對人類胰島素產品的需求。

市場動態：

人類胰島素製劑的全球市場成長主要是由於肥胖、久坐的生活方式、人口老化和遺傳因素導致的糖尿病盛行率不斷上升所推動。據世界衛生組織稱，糖尿病是導致死亡的主要原因之一，估計每年有 150 萬人死於糖尿病。人們對胰島素治療和胰島素給藥的各種創新藥物輸送選擇（例如胰島素幫浦和筆）的認知不斷提高，可能會推動市場成長。然而，人類胰島素製劑的高價格可能會阻礙市場成長。生物相似藥人類胰島素製劑市場的開拓為參與企業提供了利潤豐厚的成長機會。

本研究的主要特點

• 該報告對全球人類胰島素製劑市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還揭示了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的重要見解。
• 它根據公司亮點、產品系列、主要亮點、財務表現和策略等參數，介紹了全球人類胰島素製劑市場的主要企業。
• 主要企業包括賽諾菲、諾和諾德公司、Biocon Limited、輝瑞公司、禮來公司、Wockhardt Ltd.、SEDICO、Exir、Aventis、Merck &Co., Inc.、Julphar、GLENMARK PHARMACEUTICALS LTD.、Boehringer 包括 Ingelheim國際有限公司、Mylan NV 等
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
• 全球人類胰島素製劑市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 透過分析全球人類胰島素製劑市場時所使用的各種策略矩陣，將促進相關人員的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行概述
• 一致的機會地圖 (COM)

第3章市場動態、法規及趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 機會
• 影響分析
• 市場趨勢
• 監管場景
• 製造商收益
• 收購和合作場景
• 產品發布/核准
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章全球人類胰島素製劑市場 - 冠狀病毒（COVID-19）大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第5章全球人類胰島素製劑市場，依產品類型，2019-2031（十億美元）

• 介紹
• 人類胰島素
• 基礎胰島素
• Bolus胰島素
• 多重胰島素
• 胰島素生物相似藥

第6章全球人類胰島素製劑市場，按類型，2019-2031（十億美元）

• 介紹
• 短效
• 長效

第7章 全球人類胰島素製劑市場，依應用分類，2019-2031 年（十億美元）

• 介紹
• 1型糖尿病
• 2型糖尿病

第8章全球人類胰島素製劑市場，按地區，2019-2031（十億美元）

• 介紹
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東

第9章 競爭格局

• 公司簡介
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck &Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH.
  • Mylan NV

第10章分析師建議

• 升起和降落
• 綜合機會圖

第11章 參考文獻與調查方法

• 參考
• 調查方法

Global human insulin drug market is estimated to be valued at USD 52.47 Bn in 2024 and is expected to reach USD 92.63 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031.

Figure 1. Human Insulin Drug Market Share (%), By Region, 2024

Global human insulin drug market has been witnessing steady growth over the past few years, owing to increasing prevalence of diabetes across the world. Human insulin drugs are biosynthetically manufactured versions of regular human insulin that is used for the treatment and management of diabetes. According to the data published by the International Diabetes Federation, approximately 463 million adults lived with diabetes in 2019 and the number is expected to rise to 700 million by 2045. Growing diabetic population, rising awareness about insulin therapy, introduction of innovative insulin drug delivery systems such as insulin pens and pumps are expected to boost demand for human insulin drugs globally.

Market Dynamics:

Global human insulin drug market growth is primarily driven by growing incidence of diabetes owing to obesity, sedentary lifestyle, aging population, and genetic factors. According to WHO, diabetes is one of the major causes of death with an estimated 1.5 million deaths caused by diabetes every year. Rising awareness about insulin therapy and various innovative drug delivery options for insulin administration such as insulin pumps and pens can drive the market growth. However, high cost of human insulin drugs can hamper the market growth. The development of biosimilar human insulin drugs provides lucrative growth opportunities for players in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global human insulin drug market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human insulin drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this includes Sanofi, Novo Nordisk A/S, Biocon Limited, Pfizer Inc., Eli Lilly and Company, Wockhardt Ltd., SEDICO, Exir, Aventis , Merck & Co., Inc., Julphar, GLENMARK PHARMACEUTICALS LTD., Boehringer Ingelheim International GmbH, Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human insulin drug market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human insulin drug market

Detailed Segmentation-

• By Product Type:
  • Human Insulin
  • Basal Insulin
  • Bolus Insulin
  • Insulin Combinations
  • Biosimilar Insulins
• By Type:
  • Short Acting
  • Long Acting
• BY Application:
  • Type 1 Diabetes
  • Type 2 Diabetes
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Sanofi
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH
  • Mylan N.V.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Product Type
  • Market Snapshot, By Type
  • Market Snapshot, By Application
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Human Insulin Drug Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Human Insulin Drug Market, By Product Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Human Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Basal Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bolus Insulin
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Insulin Combinations
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Biosimilar Insulins
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Human Insulin Drug Market, By Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Short Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Long Acting
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Human Insulin Drug Market, By Application, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2020 - 2031
  • Segment Trends
• Type 1 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Type 2 Diabetes
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Human Insulin Drug Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Application, 2019 - 2031, (USD Bn)
  • Forecast, and Y-o-Y Growth, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Sanofi*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novo Nordisk A/S
  • Biocon Limited
  • Pfizer Inc.
  • Eli Lilly and Company
  • Wockhardt Ltd.
  • SEDICO
  • Exir
  • Aventis
  • Merck & Co., Inc.
  • Julphar
  • GLENMARK PHARMACEUTICALS LTD.
  • Boehringer Ingelheim International GmbH.
  • Mylan N.V.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact